Glycyron

Role

Indications

Reactions

Secondary

Glomerulonephritis Membranous	20.8%
Hypertension	16.2%
Product Used For Unknown Indication	8.1%
Rheumatoid Arthritis	7.5%
Hepatitis C	5.8%
Insomnia	5.2%
Neuropathy Peripheral	4.6%
Pemphigoid	4.6%
Drug Use For Unknown Indication	3.5%
Hepatic Function Abnormal	3.5%
Type 2 Diabetes Mellitus	3.5%
Constipation	2.3%
Depression	2.3%
Osteoporosis	2.3%
Hepatic Cirrhosis	1.7%
Oedema	1.7%
Oedema Due To Hepatic Disease	1.7%
Prophylaxis	1.7%
Thrombosis Prophylaxis	1.7%
Anorexia	1.2%

Toxic Epidermal Necrolysis	12.0%
White Blood Cell Count Decreased	12.0%
Intentional Drug Misuse	8.0%
Liver Disorder	8.0%
Sensation Of Heaviness	8.0%
Thrombotic Thrombocytopenic Purpura	8.0%
Treatment Noncompliance	8.0%
Antimitochondrial Antibody Positive	4.0%
Aspartate Aminotransferase Increased	4.0%
Blood Creatine Phosphokinase Increased	4.0%
Dizziness	4.0%
Hyperuricaemia	4.0%
Pleurisy	4.0%
Renal Impairment	4.0%
Ventricular Extrasystoles	4.0%
White Blood Cell Count Increased	4.0%

Concomitant

Prophylaxis	19.1%
Hepatitis C	11.3%
Hypertension	11.1%
Chronic Hepatitis C	9.7%
Drug Use For Unknown Indication	6.3%
Product Used For Unknown Indication	4.6%
Hepatic Neoplasm Malignant	3.8%
Insomnia	3.5%
Metastatic Renal Cell Carcinoma	3.4%
Hepatic Function Abnormal	3.2%
Rheumatoid Arthritis	3.1%
Breast Cancer	2.8%
Constipation	2.6%
Hiv Infection	2.5%
Liver Disorder	2.5%
Infection Prophylaxis	2.3%
Gastritis	2.2%
Aplastic Anaemia	2.1%
Diabetes Mellitus	2.1%
Pneumonia	1.8%

Rash	11.2%
Renal Impairment	8.6%
Pyrexia	7.8%
Drug Eruption	7.4%
Liver Disorder	7.4%
White Blood Cell Count Increased	7.4%
Osteitis	5.6%
Hepatic Function Abnormal	5.2%
Vomiting	4.5%
White Blood Cell Count Decreased	4.5%
Palmar-plantar Erythrodysaesthesia Syndrome	4.1%
Neutrophil Count Decreased	3.7%
Interstitial Lung Disease	3.3%
Renal Failure Acute	3.3%
Urine Abnormality	3.0%
Ascites	2.6%
Cardiac Failure	2.6%
Hepatic Neoplasm Malignant	2.6%
Metabolic Encephalopathy	2.6%
Pancytopenia	2.6%